COLTENE Holding stock
CLTN.SWSIXCOLTENE Holding AG, HealthcareISIN CH0025343259
61Score 61 out of 100, Neutral
Price and trend
54 / 100
Price history
+1.9% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 2.4% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 17% below its 52-week high. Largest decline in 20 years: 75% (April 2007 to June 2012).
Chart figures for advanced users
- SMA 50$56.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$59.82
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$54.23
- The lowest closing price of the last twelve months.
- Resistance$70.13
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- COLTENE Holding AG belongs to the Medical (Instruments & Supplies) industry (Switzerland) and, with a market value of $348.86M, is number 44 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $289.26M (down 4% year on year) and earnings of $18.01M (down 27%).
- MEQIRI Score 61 out of 100 (Neutral): rank 260 of 714 in Healthcare, median 53.
Show more
- The P/E is 19.7 (Medical (Instruments & Supplies) median 34.8, own median of recent years 21.3).
- Our model puts fair value at $97.85, with the price 41% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 41% below the fair value of $97.85.Valuation 85
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 86
- High dividend yieldDividend yield 4.18%, Medical (Instruments & Supplies) median 0.88%.
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and valuation, while capital allocation and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $75.27 and expensive above $139.79 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $92.42 (cash-flow model) and $103.28 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 5.6%. At 6.6% the fair value would be $89.31, at 4.6% it would be $110.72.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 2.5% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 26%, operating 9%, net 6%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 5 Mar 2027in 113 days
- Last reported
- 31 Jul 2026EPS reported $0.82
Analyst estimates
Analysts have cut their 2027 earnings estimate by 9.4% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $2.29−22.3%
- Revenue
- $288M+0.8%
- Earnings per share
- $3.37−9.4%
- Revenue
- $295.23M+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at COLTENE Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger companies by market value
- SKAN GroupSKAN.SW $1.88B72
- LeMaitre VascularLMAT $1.81B70
- STAAR SurgicalSTAA $1.34B45
- GerresheimerGXI.DE $1.23B48
- Safilo GroupSFL.MI $952.24M61
- Dynavox GroupDYVOX.ST $784.94M66
- AngioDynamicsANGO $522.32M40
- EmbectaEMBC $369.99M63
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Jul 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.